Logo image of ZOM

ZOMEDICA CORP (ZOM) Stock Fundamental Analysis

NYSEARCA:ZOM - NYSE Arca - CA98980M1095 - Common Stock - Currency: USD

0.1198  0 (-0.66%)

After market: 0.1199 +0 (+0.08%)

Fundamental Rating

3

Taking everything into account, ZOM scores 3 out of 10 in our fundamental rating. ZOM was compared to 190 industry peers in the Health Care Equipment & Supplies industry. While ZOM has a great health rating, there are worries on its profitability. ZOM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ZOM has reported negative net income.
In the past year ZOM has reported a negative cash flow from operations.
ZOM had negative earnings in each of the past 5 years.
In the past 5 years ZOM always reported negative operating cash flow.
ZOM Yearly Net Income VS EBIT VS OCF VS FCFZOM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

ZOM has a Return On Assets (-29.05%) which is comparable to the rest of the industry.
The Return On Equity of ZOM (-30.66%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -29.05%
ROE -30.66%
ROIC N/A
ROA(3y)-8.76%
ROA(5y)-104.96%
ROE(3y)-9.18%
ROE(5y)-199.7%
ROIC(3y)N/A
ROIC(5y)N/A
ZOM Yearly ROA, ROE, ROICZOM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

With an excellent Gross Margin value of 69.64%, ZOM belongs to the best of the industry, outperforming 80.85% of the companies in the same industry.
ZOM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZOM Yearly Profit, Operating, Gross MarginsZOM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400 -500

More info and screens

8

2. Health

2.1 Basic Checks

ZOM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ZOM has about the same amount of shares outstanding.
ZOM has more shares outstanding than it did 5 years ago.
ZOM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZOM Yearly Shares OutstandingZOM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M
ZOM Yearly Total Debt VS Total AssetsZOM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 4.85 indicates that ZOM is not in any danger for bankruptcy at the moment.
ZOM has a Altman-Z score of 4.85. This is in the better half of the industry: ZOM outperforms 77.13% of its industry peers.
There is no outstanding debt for ZOM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.85
ROIC/WACCN/A
WACC9.02%
ZOM Yearly LT Debt VS Equity VS FCFZOM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

ZOM has a Current Ratio of 10.82. This indicates that ZOM is financially healthy and has no problem in meeting its short term obligations.
ZOM has a Current ratio of 10.82. This is amongst the best in the industry. ZOM outperforms 94.15% of its industry peers.
ZOM has a Quick Ratio of 10.15. This indicates that ZOM is financially healthy and has no problem in meeting its short term obligations.
ZOM has a better Quick ratio (10.15) than 94.15% of its industry peers.
Industry RankSector Rank
Current Ratio 10.82
Quick Ratio 10.15
ZOM Yearly Current Assets VS Current LiabilitesZOM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ZOM have decreased strongly by -57.89% in the last year.
ZOM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.33%.
EPS 1Y (TTM)-57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
Revenue 1Y (TTM)11.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.29%

3.2 Future

The Earnings Per Share is expected to decrease by -7.13% on average over the next years.
ZOM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.91% yearly.
EPS Next Y-110.78%
EPS Next 2Y-14.78%
EPS Next 3Y-5.84%
EPS Next 5Y-7.13%
Revenue Next Year10.67%
Revenue Next 2Y19.02%
Revenue Next 3Y22.19%
Revenue Next 5Y23.91%

3.3 Evolution

ZOM Yearly Revenue VS EstimatesZOM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M 50M
ZOM Yearly EPS VS EstimatesZOM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.05 -0.1 -0.15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZOM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZOM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZOM Price Earnings VS Forward Price EarningsZOM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZOM Per share dataZOM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15 0.2

4.3 Compensation for Growth

ZOM's earnings are expected to decrease with -5.84% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.78%
EPS Next 3Y-5.84%

More info and screens

0

5. Dividend

5.1 Amount

ZOM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZOMEDICA CORP

NYSEARCA:ZOM (2/21/2025, 8:04:00 PM)

After market: 0.1199 +0 (+0.08%)

0.1198

0 (-0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners9.39%
Inst Owner Change-97.78%
Ins Owners0.74%
Ins Owner Change1.84%
Market Cap117.40M
Analysts80
Price Target0.26 (117.03%)
Short Float %4.64%
Short Ratio7.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-23.83%
Min Revenue beat(2)-27.36%
Max Revenue beat(2)-20.3%
Revenue beat(4)1
Avg Revenue beat(4)-17.04%
Min Revenue beat(4)-27.36%
Max Revenue beat(4)3.78%
Revenue beat(8)1
Avg Revenue beat(8)-16.36%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-380%
EPS NY rev (3m)-380%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-19.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.39
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB 1.11
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.03
BVpS0.21
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.05%
ROE -30.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.64%
FCFM N/A
ROA(3y)-8.76%
ROA(5y)-104.96%
ROE(3y)-9.18%
ROE(5y)-199.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 86.87%
Cap/Sales 25.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.82
Quick Ratio 10.15
Altman-Z 4.85
F-Score4
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)120.38%
Cap/Depr(5y)90.3%
Cap/Sales(3y)29.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
EPS Next Y-110.78%
EPS Next 2Y-14.78%
EPS Next 3Y-5.84%
EPS Next 5Y-7.13%
Revenue 1Y (TTM)11.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.29%
Revenue Next Year10.67%
Revenue Next 2Y19.02%
Revenue Next 3Y22.19%
Revenue Next 5Y23.91%
EBIT growth 1Y-50.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-88.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70%
OCF growth 3YN/A
OCF growth 5YN/A